Effect of Redon-type Drains on Postoperative Edema Following Mandibular Orthognathic Surgery: a Randomized, Controlled Superiority Trial With Two Parallel Arms (DPO - OM)
Orthognathic surgery involves the maxillary and/or mandibular skeletal bases; it entails maxillary and/or mandibular osteotomies (such as sagittal split osteotomies of the mandibular rami) aimed at restoring normal maxillomandibular skeletal and dento-occlusal relationships in patients with maxillomandibular dysmorphosis. These deformities give rise to morphological, aesthetic, and functional abnormalities that can be severe (e.g., respiratory issues, temporomandibular joint pain). Postoperative edema is inevitable following orthognathic surgery; it can be significant, causing pain and discomfort while delaying patient recovery and hospital discharge. The use of Redon-type drains for mandibular osteotomies is not a standard practice across surgical teams due to a lack of consensus. The only available data come from studies with methodologies that do not allow for a definitive conclusion regarding the superiority of using-or not using-postoperative Redon drains (Lee et al. 2020), and no clinical trials have investigated this issue. This project aims to evaluate the impact of Redon-type drainage in mandibular osteotomies (sagittal split osteotomies of the mandibular rami), whether or not combined with genioplasty (osteotomy of the mental symphysis). We hypothesize that drainage using Redon-type drains for 6 hours in the immediate postoperative period following mandibular osteotomies significantly reduces postoperative edema.
The primary objective of this clinical trial is to demonstrate the superiority-in terms of reducing postoperative edema at day 2-of placing Redon-type drains for 6 hours immediately following sagittal split osteotomy of the mandibular rami (in addition to standard postoperative care) compared to standard postoperative care alone, without a drainage device.
Hypothesis: Demonstrating that the use of Redon-type drains following orthognathic surgery osteotomies reduces postoperative edema, pain, and discomfort would provide a rational basis for this practice and support its routine implementation. The expected benefits are twofold, impacting both patients and public health. For patients, the anticipated benefits include reduced postoperative discomfort and pain, faster recovery, and shorter hospital stays, with the future prospect of outpatient care.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Anne MORICE, DR
- Telefonnummer: 0247476680
- E-Mail: a.morice@chu-tours.fr
Studienorte
-
-
-
Angers, Frankreich
- Chu Angers
-
Nantes, Frankreich
- Chu Nantes
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria:
-
Patients aged 15 years or older
-
Undergoing mandibular osteotomies, with or without genioplasty, with or without wisdom tooth extraction (maxillary and/or mandibular)
-
Informed consent obtained from the adult patient, or from the holder(s) of parental authority if the patient is a minor*
-
Enrolled in a French social security program
- When both holders of parental authority cannot give joint consent, the consent of a single legal representative may be obtained in situations provided for by regulations or duly justified and documented in the source file.
Exclusion Criteria:
- History of maxillomandibular bone surgery
- Coagulation disorder
- Thrombophilia
- Patients on anticoagulants or antiplatelet agents
- Patients with a constitutional bone disorder
- Patients with a syndromic craniofacial malformation
- Absolute or relative contraindications to treatment with corticosteroids
- Pregnant (urine test) or breastfeeding women
- Patients under legal guardianship, conservatorship, or judicial protection
- Contraindications to the procedure
- Patients who have taken corticosteroids or NSAIDs on the day before the procedure (D-1).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: experimental arm
with drains placed at the end of the procedure, in addition to standard postoperative care. These will be Redon drains with an outlet that is either intraoral or transcutaneous in the cervical region, depending on the participating center's practices (intraoral transmucosal in the Tours and Angers centers or transcutaneous in the Nantes center); these drains will be removed 6 hours after placement Translated with DeepL.com (free version) |
in which drains are placed at the end of the procedure, in addition to standard postoperative care. |
|
Aktiver Komparator: control arm
which consists of not placing any drainage device immediately after surgery, with standard postoperative care identical to that of the experimental group. |
not placing any drainage device immediately after surgery, with standard postoperative care identical |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postoperative swelling
Zeitfenster: Cervicofacial linear measurement will be collected 48 hours after the randomization (day 2) and at month 3. As the facial skeletal anatomy will be modified by the surgical procedure, month 3 will be considered as the baseline measurement.
|
The primary outcome will be the post operative facial swelling 48 hours after the end of the surgical procedure (randomization will be at this timepoint) measured with cervicofacial linear measurements |
Cervicofacial linear measurement will be collected 48 hours after the randomization (day 2) and at month 3. As the facial skeletal anatomy will be modified by the surgical procedure, month 3 will be considered as the baseline measurement.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postoperative swelling
Zeitfenster: Cervicofacial linear measurement will be collected at 6 hours after randomization, 24 hours after randomization (day 1) and at day 7
|
Postoperative swelling at other time points than for the primary outcome, measured with cervico facial linear measurements |
Cervicofacial linear measurement will be collected at 6 hours after randomization, 24 hours after randomization (day 1) and at day 7
|
|
Postoperative swelling
Zeitfenster: It will be collected 24 hours after randomization (day 1) , at day 2, at day 7 and at month 3
|
Postoperative swelling using 3D photogrammetry instead of cervicofacial linear measurements |
It will be collected 24 hours after randomization (day 1) , at day 2, at day 7 and at month 3
|
|
Pain intensity
Zeitfenster: Pain will be collected 6 hours after randomization, at day 1 (24 hours after randomization), at day 2 and at day 7
|
Pain will be measured using a visual analog scale where 0 corresponds to no pain and 10 to unbearable pain |
Pain will be collected 6 hours after randomization, at day 1 (24 hours after randomization), at day 2 and at day 7
|
|
Aesthetic discomfort
Zeitfenster: It will be collected 6 hours after randomization, at day 1 (24 hours after randomization), at day 2 and at day 7
|
Aesthetic discomfort will be measured using a visual analog scale with 0 indicating no discomfort and 10 corresponding to an extremely uncomfortable feeling |
It will be collected 6 hours after randomization, at day 1 (24 hours after randomization), at day 2 and at day 7
|
|
Breathing discomfort
Zeitfenster: It will be collected 6 hours after randomization, at day 1 (24 hours after randomization), at day 2 and at day 7
|
Breathing discomfort will be measured using a visual analog scale where 0 corresponds to no discomfort and 10 to extremely bothersome |
It will be collected 6 hours after randomization, at day 1 (24 hours after randomization), at day 2 and at day 7
|
|
Swallowing discomfort
Zeitfenster: It will be collected 6 hours after randomization, at day 1 (24 hours after randomization), at day 2 and at day 7
|
Swallowing discomfort will be measured using a visual analog scale where 0 corresponds to no discomfort and 10 to extremely bothersome |
It will be collected 6 hours after randomization, at day 1 (24 hours after randomization), at day 2 and at day 7
|
|
Pain during redon drain removal
Zeitfenster: It will be collected 6 hours after randomization, at time to redon removal.
|
Pain during redon drain removal will be collected for participants of the experimental group after redon drain removal |
It will be collected 6 hours after randomization, at time to redon removal.
|
|
The daily bed rest in hours
Zeitfenster: It will be collected at day 1 and at day 2 (how long the participant stay in his bed in the last 24 hours) as well as at day 7 (how long the participants stay in his bed each day of the last 4 days).
|
It corresponds to how long, in hours, the participant stays in his bed each day. |
It will be collected at day 1 and at day 2 (how long the participant stay in his bed in the last 24 hours) as well as at day 7 (how long the participants stay in his bed each day of the last 4 days).
|
|
The general well-being
Zeitfenster: It will be collected at day 7 and at month 3
|
General well-being will be assessed using the GHQ-28 self-assessment questionnaire. The GHQ-28 is a questionnaire with 28 items and with scores ranging from 0 - indicating no deterioration in well-being - to 84 - indicating a significant deterioration in well-being. |
It will be collected at day 7 and at month 3
|
|
The length of hospital stay
Zeitfenster: a maximum of 90 days
|
It corresponds to the lenght of the hospital stay, in days (a maximum of 90 days) |
a maximum of 90 days
|
|
Postoperative adverse events
Zeitfenster: Throughout the three-month follow-up period, whenever an adverse event occurs
|
Postoperative adverse events correspond to hematoma, pre-thoracic hematoma spread, and infection |
Throughout the three-month follow-up period, whenever an adverse event occurs
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Anne MORICE, Dr, University Hospital, Tours
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- DR260063 - DPO OM
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .